Cabozantinib Versus Sunitinib for Untreated Patients with Advanced Renal Cell Carcinoma of Intermediate or Poor Risk: Subgroup Analysis of the Alliance A031203 CABOSUN trial

被引：18

作者：

George, Daniel J. ^{[1
]}

Hessel, Colin ^{[2
]}

Halabi, Susan ^{[3
,4
]}

Michaelson, M. Dror ^{[5
]}

Hahn, Olwen ^{[6
]}

Walsh, Meghara ^{[7
]}

Picus, Joel ^{[8
]}

Small, Eric J. ^{[9
]}

Dakhil, Shaker ^{[10
]}

Feldman, Darren R. ^{[11
]}

Mangeshkar, Milan ^{[2
]}

Scheffold, Christian ^{[2
]}

Morris, Michael J. ^{[11
]}

Choueiri, Toni K. ^{[7
]}

机构：

[1] Duke Univ, Med Ctr, Duke Canc Inst, Durham, NC USA

[2] Exelixis Inc, Alameda, CA USA

[3] Duke Univ, Alliance Stat & Data Ctr, Durham, NC USA

[4] Duke Univ, Dept Biostat & Bioinformat, Durham, NC USA

[5] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA

[6] Alliance Protocol Operat Off, Chicago, IL USA

[7] Dana Farber Partners CancerCare, Boston, MA USA

[8] Washington Univ, Siteman Canc Ctr, Sch Med, St Louis, MO USA

[9] UCSF Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA

[10] Univ Kansas Wichita, Wichita, KS USA

[11] Memorial Sloan Kettering Canc Ctr, New York, NY USA

来源：

ONCOLOGIST | 2019年 / 24卷 / 11期

关键词：

THERAPY;

D O I：

10.1634/theoncologist.2019-0316

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Cabozantinib treatment prolonged progression-free survival (PFS) and improved objective response rate (ORR) compared with sunitinib in patients with advanced renal cell carcinoma (RCC) of intermediate or poor risk by International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) criteria in the phase II CABOSUN trial (NCT01835158). In the trial, 157 patients were randomized 1:1 to receive cabozantinib or sunitinib, stratified by IMDC risk group and presence of bone metastases. Here, PFS and ORR, both determined by independent radiology committee (IRC), were analyzed by subgroups of baseline characteristics. Cabozantinib treatment was generally associated with improved PFS and ORR versus sunitinib across subgroups, including in groups defined by IMDC risk group, bone metastases, age, and tumor burden. Clinical trial identification number. NCT01835158.

引用

页码：1497 / 1501

页数：5

共 50 条

[31] Bempegaldesleukin Plus Nivolumab Versus Sunitinib or Cabozantinib in Previously Untreated Advanced Clear Cell Renal Cell Carcinoma: A Phase III Randomized Study (PIVOT-09)
Tannir, Nizar M.
Formiga, Maria Nirvana
Penkov, Konstantin
Kislov, Nikolay
Vasiliev, Aleksandr
Skare, Nils Gunnar
Hong, Walter
Dai, Stanley
Tang, Lily
Qureshi, Anila
Zalevsky, Jonathan
Tagliaferri, Mary A.
George, Daniel
Agarwal, Neeraj
Pal, Sumanta
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (23)
[32] Activity and safety of sunitinib in poor risk metastatic renal cell carcinoma patients
Barroso-Sousa, Romualdo
Munhoz, Rodrigo R.
Mak, Milena P.
Fonseca, Leonardo G.
Fede, Angelo B. S.
Marques Linck, Rudinei Diogo
Coelho, Clovis R.
Moniz, Camila M. V.
Souza, Ciro E.
Dzik, Carlos
INTERNATIONAL BRAZ J UROL, 2014, 40 (06): : 835 - 841
[33] Cabozantinib exposure-response analysis for the phase 3 CheckMate 9ER trial of nivolumab plus cabozantinib versus sunitinib in first-line advanced renal cell carcinoma
Tran, Benjamin Duy
Li, Jing
Ly, Neang
Faggioni, Raffaella
Roskos, Lorin
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2023, 91 (02) : 179 - 189
[34] Temporal Trends in Grade 3/4 Adverse Events and Associated Costs of Nivolumab Plus Cabozantinib Versus Sunitinib for Previously Untreated Advanced Renal Cell Carcinoma
Geynisman, Daniel M.
Burotto, Mauricio
Porta, Camillo
Suarez, Cristina
Bourlon, Maria T.
Huo, Stephen
Del Tejo, Viviana
Du, Ella X.
Yang, Xiaoran
Betts, Keith A.
Choueiri, Toni K.
McGregor, Bradley
CLINICAL DRUG INVESTIGATION, 2022, 42 (07) : 611 - 622
[35] Temporal Trends in Grade 3/4 Adverse Events and Associated Costs of Nivolumab Plus Cabozantinib Versus Sunitinib for Previously Untreated Advanced Renal Cell Carcinoma
Daniel M. Geynisman
Mauricio Burotto
Camillo Porta
Cristina Suarez
Maria T. Bourlon
Stephen Huo
Viviana Del Tejo
Ella X. Du
Xiaoran Yang
Keith A. Betts
Toni K. Choueiri
Bradley McGregor
Clinical Drug Investigation, 2022, 42 : 611 - 622
[36] COST-EFFECTIVENESS OF CABOZANTINIB VERSUS SUNITINIB OR PAZOPANIB AS FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED RENAL CELL CARCINOMA IN THE UK
Skentzou, E.
Meng, J.
Lister, J.
Gray, L.
VALUE IN HEALTH, 2018, 21 : S30 - S30
[37] Pazopanib versus sunitinib in Chinese patients with locally advanced or metastatic renal cell carcinoma: pooled subgroup analysis from the randomized, COMPARZ studies
Sheng, Xinan
Jin, Jie
He, Zhisong
Huang, Yiran
Zhou, Aiping
Wang, Jinwan
Ren, Xiubao
Ye, Dingwei
Zhang, Xu
Qin, Shukui
Zhou, Fangjian
Wang, Binhui
Guo, Jun
BMC CANCER, 2020, 20 (01)
[38] Cost-effectiveness analysis of nivolumab plus cabozantinib versus sunitinib as first-line therapy in advanced renal cell carcinoma
Liu, Ruizhe
Qiu, Kaifeng
Wu, Junyan
Jiang, Yanqing
Wu, Peihao
Pang, Jianxin
IMMUNOTHERAPY, 2022, 14 (11) : 859 - 869
[39] Pazopanib versus sunitinib in Chinese patients with locally advanced or metastatic renal cell carcinoma: pooled subgroup analysis from the randomized, COMPARZ studies
Xinan Sheng
Jie Jin
Zhisong He
Yiran Huang
Aiping Zhou
Jinwan Wang
Xiubao Ren
Dingwei Ye
Xu Zhang
Shukui Qin
Fangjian Zhou
Binhui Wang
Jun Guo
BMC Cancer, 20
[40] A phase III study (COSMIC-313) of cabozantinib (C) in combination with nivolumab (N) and ipilimumab (I) in patients (pts) with previously untreated advanced renal cell carcinoma (aRCC) of intermediate or poor risk
Choueiri, Toni K.
Albiges, Laurence
Powles, Thomas
Scheffold, Christian
Wang, Fong
Motzer, Robert J.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)

← 1 2 3 4 5 →